AUPH
$15.47
+$0.22 (1.45%)+1.45%
After HoursLoading chart...
IndexN/A
Market Cap1.99B
Enterprise Value2.14B
Income$0.02B
Sales$0.06B
EmployeesN/A
P/E15.17
P/S7.57
P/B3.69
P/C15.83
EV/EBITDA16.73
EV/SalesN/A
EPS (ttm)1.02
EarningsN/A
Gross Margin88.46%
Oper. Margin37.06%
Profit Margin101.47%
Volume0.81M
Shs Outstand0.13B
Change1.91%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $235.13M | $175.51M | $134.03M | $45.60M | $50.12M | $318.00K | $463.00K | $420.00K |
| Cost of Revenue | $28.25M | $14.15M | $5.66M | $1.09M | $0.00 | $0.00 | $41.38M | $1.00K |
| Gross Profit | $206.88M | $161.37M | $128.37M | $44.51M | $50.12M | $318.00K | $-40.92M | $419.00K |
| Gross Margin | 87.99% | 91.94% | 95.77% | 97.61% | 100.00% | 100.00% | -8837.80% | 99.76% |
| Operating Expenses | $211.57M | $253.06M | $239.84M | $225.25M | $154.41M | $91.26M | $15.24M | $47.48M |
| Operating Income | $-4.69M | $-91.69M | $-111.47M | $-180.74M | $-104.29M | $-90.94M | $-56.16M | $-47.06M |
| Operating Margin | -1.99% | -52.24% | -83.17% | -396.31% | -208.09% | -28598.43% | -12129.16% | -11205.48% |
| Net Income | $5.75M | $-78.02M | $-108.18M | $-180.97M | $-102.68M | $-88.39M | $-64.12M | $-70.79M |
| Net Margin | 2.45% | -44.45% | -80.71% | -396.81% | -204.88% | -27794.03% | -13848.81% | -16855.24% |
| EPS (Basic) | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 | $-1.33 | $-0.76 | $-0.92 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $550.64M | $548.06M | $470.86M | $543.37M | $463.66M | $324.30M | $145.86M | $189.85M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $173.17M | $170.11M | $65.42M | $64.28M | $55.91M | $25.70M | $33.29M | $24.10M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $377.48M | $377.95M | $405.44M | $479.09M | $407.75M | $298.60M | $112.58M | $165.74M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $377.48M | $377.95M | $405.44M | $479.09M | $407.75M | $298.60M | $112.58M | $165.74M |
| Total Liabilities & Stockholders Equity | $550.64M | $548.06M | $470.86M | $543.37M | $463.66M | $324.30M | $145.86M | $189.85M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $5.75M | $-78.02M | $-108.18M | $-180.97M | $-102.68M | $-88.39M | $-64.12M | $-70.79M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $44.39M | $-33.46M | $-79.53M | $-157.69M | $-69.86M | $-63.59M | $-51.61M | $-41.17M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing TreatmentsGlobeNewswire Inc. New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global InsightsGlobeNewswire Inc. Corporate and Individual Donations Provide Much-Needed Support to Kidney Patients Impacted by Hurricane Helene Through the American Kidney Fund’s Disaster Relief ProgramGlobeNewswire Inc. Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?Zacks Investment Research How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%Zacks Investment Research Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionBenzinga
Show 12 more stories
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?Zacks Investment Research Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?Zacks Investment Research Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey MedicalZacks Investment Research 5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New YearZacks Investment Research Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?Zacks Investment Research Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High?Zacks Investment Research Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?Zacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Bailey Jeffrey Allen
F
2.7K
$15.68
$43K
Nov 21, 25
Company
About the company
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Discover more
You may be interested in